Compare DSGR & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGR | AVLN |
|---|---|---|
| Founded | 1952 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1995 | 2026 |
| Metric | DSGR | AVLN |
|---|---|---|
| Price | $35.02 | $30.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $35.00 | ★ $61.80 |
| AVG Volume (30 Days) | 280.3K | ★ 422.0K |
| Earning Date | 11-05-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 212.50 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,980,023,000.00 | N/A |
| Revenue This Year | $7.71 | N/A |
| Revenue Next Year | $4.63 | N/A |
| P/E Ratio | $92.29 | ★ N/A |
| Revenue Growth | ★ 9.75 | N/A |
| 52 Week Low | $19.02 | $22.24 |
| 52 Week High | $35.30 | $40.17 |
| Indicator | DSGR | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 60.45 |
| Support Level | $34.88 | $25.86 |
| Resistance Level | $35.06 | $33.32 |
| Average True Range (ATR) | 0.11 | 2.03 |
| MACD | -0.01 | 0.78 |
| Stochastic Oscillator | 40.91 | 78.58 |
Distribution Solutions Group Inc is a specialty distribution company providing value-added distribution solutions to the maintenance, repair and operations (MRO), original equipment manufacturer (OEM) and industrial technology markets. The company operates through four reportable segments: Lawson, TestEquity, Gexpro Services and Canada Branch Division. Lawson distributes specialty products and services to the industrial, commercial, institutional and government MRO marketplace. TestEquity, which generates maximum revenue, distributes test and measurement equipment and solutions, industrial and electronic production supplies and vendor managed inventory programs. Gexpro Services is a supply chain solutions provider. The company generates majority of its revenue from United States.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.